Knight Therapeutics Revenue and Competitors

Westmount, QC CAN

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Knight Therapeutics's estimated annual revenue is currently $167M per year.(i)
  • Knight Therapeutics's estimated revenue per employee is $201,000

Employee Data

  • Knight Therapeutics has 831 Employees.(i)
  • Knight Therapeutics grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.4M12-8%N/AN/A
#2
$10.7M1005%$39.7MN/A
#3
$47.8M238N/AN/AN/A
#4
$15.5M775%N/AN/A
#5
$345.9M17218%N/AN/A
#6
$167M8318%N/AN/A
#7
$318.8M15867%N/AN/A
#8
$27.5M137-26%N/AN/A
#9
$0.4M40%N/AN/A
#10
$66.9M333N/AN/AN/A
Add Company

Knight Therapeutics Inc. (TSX: GUD) is a publicly-traded, specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products in Canada and select international markets. In addition, Knight conducts late-stage clinical development on low risk, low expense product opportunities. All of Knight’s products are sourced through partnerships.\r\n\r\nUnlike many other specialty pharmaceutical companies, Knight has the flexibility to explore opportunities in a range of therapeutic areas.

keywords:N/A

N/A

Total Funding

831

Number of Employees

$167M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Knight Therapeutics News

2022-04-17 - Knight Therapeutics Inc. (OTCMKTS:KHTRF) Given Average Rating ... Defense World

Knight Therapeutics Inc. (OTCMKTS:KHTRF) Given Average Rating ... Defense World

2022-04-17 - Knight Therapeutics Inc. (TSE:GUD) Receives Consensus ... Defense World

Knight Therapeutics Inc. (TSE:GUD) Receives Consensus ... Defense World

2022-04-13 - Knight Therapeutics Inc. (TSE:GUD) Director Robert Nathaniel ... Defense World

Knight Therapeutics Inc. (TSE:GUD) Director Robert Nathaniel ... Defense World

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M1103N/AN/A